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Abstract
Intermittent preventive treatment (IPT) administers a full therapeutic course of an anti-malarial
drug at predetermined intervals, regardless of infection or disease status. It is recommended by the
World Health Organization (WHO) for protecting pregnant women from the adverse effects of
malaria (IPTp) and shows great potential as a strategy for reducing illness from malaria during
infancy (IPTi). Administered concurrently with standard immunizations, IPTi is expected to reduce
the frequency of clinical disease, but to allow blood-stage infections to occur between treatments,
thus allowing parasite-specific immunity to develop. While wide deployment of IPTi is being
considered, it is important to assess other potential effects. Transmission conditions, drug choice
and administration schedule will likely affect the possibility of post-treatment rebound in child
morbidity and mortality and the increased spread of parasite drug resistance and should be
considered when implementing IPTi.
Background
Intermittent preventive treatment (IPT) protects pregnant
women from malaria and placental parasitaemia and
their newborns from malaria-associated low birth weight
[1-6]. This strategy is being proposed to reduce malaria
morbidity and mortality in infants (IPTi) in sub-saharan
Africa by administration of a therapeutic course of an anti-
malarial drug at predetermined intervals, regardless of
infection, during routine vaccinations of infants in the
Expanded Programme on Immunization (EPI). The inten-
tion is to clear any current infection and protect against
new infection until the drug level decays in the blood-
stream. Intervals between doses are typically longer than
the time to clear the drug from the bloodstream (Figure
1), allowing the possibility of infection between doses. In
infants, IPTi may simultaneously reduce the frequency of
infection and life-threatening disease while allowing
immunity to develop.
The context of IPTi is fundamentally distinct from that of
IPTp: recipients of IPTp have already acquired some para-
site-specific immunity, whereas infants are immunologi-
cally naïve and may comprise a disproportionately large
infectious reservoir in the community [7-9]. A theoretical
evaluation of the effect of drug pharmacokinetics on IPTi
and IPTp efficacy in the face of rising drug resistance has
recently been presented [10]. This paper discusses con-
cerns related primarily to IPTi, specifically, whether: 1)
immunity developed to malaria will be as robust in
treated as in untreated individuals, forestalling a post-
treatment increase in disease and mortality (rebound
effect), 2) differences in transmission intensity should
inform the timing of IPTi administration, 3) IPTi is likely
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to promote the spread of drug resistance, and 4) regional
differences should inform the choice of IPTi drug.
Published IPTi studies
Two published studies have examined the effect of IPTi on
malaria morbidity. Both were conducted in Tanzania and
showed significant decreases in anaemia and clinical epi-
sodes of malaria in the treated group relative to the pla-
cebo group. In the study with sulfadoxine-pyrimethamine
(SP), infants were given either a placebo or a drug three
times with vaccinations (at two, three and nine months of
age) and were followed until 22 months of age [11]. IPTi
reduced the expected number of clinical cases of malaria
in the first year of life by 59%. However, the effect
declined significantly with time after the final dose. One
month after the last dose – roughly the time to clear the
final dose of SP from the bloodstream – the clinical case
rates among infants in the control group and those in the
treated group who had not previously contracted clinical
malaria were indistinguishable and remained so until the
end of the follow-up period. The follow-up to this study
[12] reported that the protective effect of IPTi with SP
extended well into the second year of life; however, only
those children who contracted malaria during IPTi treat-
ments experienced this long-term benefit. Those who did
not contract malaria during IPTi treatments had malaria
as frequently as placebo recipients who did not contract
malaria. In the study with amodiaquine [13], infants three
to four months old were given a full course of the drug
every two months for six months and followed for four
Concentration of anti-malarial drug in bloodstream during IPT Figure 1
Concentration of anti-malarial drug in bloodstream during IPT. Drug concentration initially rises after administration 
of a therapeutic drug regimen. The concentration declines gradually as the drug is cleared from the bloodstream. Parasites with 
increasing sensitivity to the drug will be able to grow as the drug concentration declines. Parasites are divided roughly into 
three categories; fully sensitive, partially resistant and fully resistant. The interval between the time at which the concentration 
falls below the threshold for partially sensitive parasites and the time at which it falls below the threshold for sensitive parasites 
is a window of selection for resistant parasites. The dotted curve represents the target blood concentrations during 
chemoprophylaxis.
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months after the last dose. The protective efficacy against
clinical attacks of malaria was 65% during the six months
of treatment. Some protection persisted throughout the
follow-up period; by the end of the study, 35% of treated
infants remained free from a first attack of malaria com-
pared to 13% in the control group.
Thus, the results of the two published IPTi studies are
encouraging. Two other studies [14,15] using strategies
similar to IPTi failed to demonstrate statistically signifi-
cant reductions in clinical episodes of malaria. Both
administered SP at monthly intervals three times to anae-
mic children in Kenya. These children were older than
those in the two IPTi studies (mean age at enrollment = 11
[14] and 20 months [15], versus 0 [11] and three [13]
months), but still within the age range most at risk for
malaria-related morbidity and mortality in these regions
[16].
Immunity and rebound
An effective immune response to malaria is acquired
slowly and cumulatively, requiring boosting; each subse-
quent infection generates increasing protection from
severe illness, although the exact number of infections
required to achieve a protected state is unknown. Of con-
cern is whether administering anti-malarial drugs inter-
rupts development of immunity and leads to decreased
malaria-specific immunity and/or a rebound of increased
morbidity and mortality after termination of treatment.
Rebound effects have been observed in several studies of
chemoprophylaxis in children [17-21]. Using pyrimeth-
amine-dapsone (P-D), Menendez et al [17] found that
children given weekly doses during their first year had
fewer malaria episodes during that year than did controls;
in the year after termination of chemoprophylaxis, the fre-
quency of cases in the treated group was twice that of the
placebo group (Table 1). In a longer-term study, children
were given P-D or placebo every two weeks from three
months to five years of age or until the end of the five-year
study, whichever was first [18,22]; at its conclusion, the
study included children between one and ten years of age
who had been treated for up to five years. The number of
malaria episodes in the post-treatment group was greater
than in the placebo group, and the probability of death
from malaria between the age of five and six, immediately
after termination of treatment, was slightly higher in the
group that had received P-D for the full five years than in
the placebo group. However, there was a 15% overall
reduction in mortality in the treated group from age 0 to
10 years. Geerligs et al [23] review malaria chemoprophy-
laxis in children, including studies with and without
rebound effects. Von Seidlein and Greenwood [24] offer a
more general review of mass drug administration strate-
gies including chemoprophylaxis and IPT.
Among the implicit assumptions of the IPTi strategy are
that both the number of serious clinical episodes and the
development of malaria-specific immunity are directly
proportional to the frequency of infection. If these
assumptions are true, intermittent doses of drug could
reduce the frequency of serious malaria episodes, while
the intervals between doses of drug could permit infection
and the development of immunity. Thus, if suppressed
development of immunity is responsible for any rebound
effects from chemoprophylaxis, the IPTi strategy could
reduce the likelihood of rebound, provided that infectious
bites occur frequently enough to ensure exposure between
doses. There is reason to doubt whether rebound effects
are proportional to the frequency of infection and immu-
nity in infants and children, however. In the five-year
study with P-D cited above, the group that had received
the drug for the full five years had levels of malaria-spe-
cific antibodies equivalent to those in the control group
[18]. Nonetheless, they experienced more disease epi-
sodes and mortality during the first year post-chemo-
prophylaxis than those with lower antibody titres.
Parasite-specific antibody titres often correlate with expo-
sure, but not protection from disease.
The relationship between frequency of infection, immu-
nity and rebound is further complicated by evidence that
very short-term drug administration can lead to signifi-
cant rebound effects (Table 1). During a one-time mass
administration of SP-plus-artesunate to entire villages in
The Gambia at the start of the rainy season [25], the fre-
quency of malaria attacks among children under 11 years
of age in treated villages was 60% lower than in control
villages during the first six weeks. During the third month
post-treatment, disease incidence doubled in children in
the treated villages relative to the placebo villages. In
another study [26], two groups of individuals from the
same town in Mali, aged three months to 20 years, were
treated with a single dose of SP or placebo. In the first four
weeks, 5% of the treated group had at least one malaria
episode compared to 25% of the control group. During
weeks nine to 12, the incidence was twice as high in the SP
group. These last examples included much wider age
ranges than would IPTi, but they indicate that rebound
can happen over very short time periods, with only a sin-
gle dose of drug, signaling the possibility that IPTi could
show similar effects.
Neither of the published IPTi studies reported a rebound
after termination of treatment, even after extended follow-
up. However, a significant rebound of malaria morbidity
was observed in an IPTi trial conducted in Navrongo,
Ghana (D. Chandramohan, personal communication). In
this study, the number of rebound episodes apparently
did not negate the benefit of IPTi. Even so, it is imperativeMalaria Journal 2005, 4:33 http://www.malariajournal.com/content/4/1/33
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that these effects be measured and reported prior to com-
munity-wide implementation of IPTi.
Transmission effects: timing of IPTi 
administration
It is important that the conditions for which the current
conception of IPTi within the EPI delivery system will be
beneficial be defined as clearly as possible so that
resources for malaria control are allocated to the most
effective programmes in each region. Under conditions of
intense, perennial transmission, infants may be suscepti-
ble to severe clinical attacks from a few months after birth,
and antimalarials given during routine EPI visits at two,
three and nine months of age are likely to be effective in
reducing episodes of malaria. Where transmission is less
intense or unstable, children are at great risk until 5 years
of age or older. As transmission rates decline with increas-
ing urbanization and bednet usage in sub-Saharan Africa
[27,28], a larger proportion of the population will be at
greatest risk after one year of age. For example, the average
age of first malaria infection in Prampram, Ghana [29],
was estimated to be 10.5 months; here, IPTi within EPI
(final dose at nine months) is unlikely to impact malaria
morbidity. Thus, implementing IPTi uniformly and exclu-
sively at the time of EPI vaccinations may be inadequate
in many circumstances.
If the aim is to administer IPTi during the time of greatest
risk of severe disease from unprotected exposure to infec-
tion, age-incidence data for severe malaria will be needed
to target those most likely to benefit in a given location
(Figure 2). In low and moderate transmission areas, IPT
may be most effective if the schedule is extended into early
childhood. Highly seasonal malaria may require unique
strategies which target the appropriate age groups during
the transmission season. If mechanisms for delivery can
be established that allow greater flexibility in the window
of administration, IPTi could have a much broader
impact. A study of IPT in children under five in an area of
highly seasonal transmission administered doses of SP at
monthly intervals exclusively during the high transmis-
sion season. This approach reduced the incidence of clin-
ical malaria by more than 80% in the treated group
compared to the control group, indicating that adapting
the IPT schedule can be accomplished with good results
[30].
The relationship between the age interval during which
IPTi is administered and that of greatest risk will
Table 1: Comparison of studies during which a rebound effect was observed upon termination of drug treatment. Studies are in the 
order they are cited in the text.
Drug used 
(country)
Ages of study 
group
Duration of 
treatment
Duration of 
post-
intervention 
follow-up
Effect on malaria 
morbidity
Rebound effect Reference
P-D1 (Tanzania) 2 mo. at start of 
study
Weekly for one 
year
One year after 
termination of 
treatment
Reduced incidence 
of clinical malaria 
by 40% during 
treatment period
80% higher incidence of 
clinical episodes in 
treated group during the 
year following 
termination of 
treatment
[17]
P-D (The Gambia) 3 mo. at start of 
study
Every 2 weeks for 
maximum of 5 
years
5 years 65% reduction in 
malaria episodes 
after 3 years of 
chemoprophylaxis
52% more cases in 
treated group during the 
year following 
termination of 
treatment
[18, 22]
SP2 + artesunate 
(The Gambia)
Entire villages, all 
ages
MDA3 1 dose 20 weeks Reduced rate of 
malaria attacks in 
children <11 yr by 
60%
Rate of clinical malaria 
was 69% higher in 
treated groups 3 
months after treatment
[25]
SP (Mali) 3 mo. to 20 years MDA 1 dose 24 weeks Reduced incidence 
of first malaria 
episode from 26% 
to 3% during first 
month
Incidence of first malaria 
episodes in treated 
group rose to 42% 
compared to 17% 
(untreated group) 
during the third month 
after treatment
[26]
1P-D: pyrimethamine-dapsone
2SP: sulfadoxine-pyrimethamine
3MDA: mass drug administrationMalaria Journal 2005, 4:33 http://www.malariajournal.com/content/4/1/33
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determine the overall benefit of IPTi, i.e. reduction in the
total number of malaria cases. In the published SP study
[11], prevalence among 12-month old infants was only
4% (annual Entomological Inoculation Rate = 29 [31])
whereas in the amodiaquine study the prevalence in 3.5
month-olds was 24–34% (EIR = 400). Although protec-
tive efficacy, or the percentage reduction in first clinical
episodes, was similar between the two studies (59% and
65%), only 0.26 cases per person-year at risk were pre-
vented in the SP study versus 1.49 cases in the amodi-
aquine study.
The frequency and clustering of infectious bites deter-
mines whether the time interval between doses will per-
mit the development of immunity, and whether IPTi will
act primarily to protect against infection or treat existing
infections (Figure 3). Exposure to infectious bites must be
sufficiently frequent, or IPT doses sufficiently spaced, to
allow infection between periods of protection. Although
the relationship between infection and development of
clinical immunity remains poorly understood, it is clear
that if no infectious bites are received between treatments,
then IPTi will be functionally equivalent to
chemoprophylaxis.
Transmission intensity may vary considerably over very
short distances and short time periods. While it will often
be impractical to vary drug administration schedules in
response, broader assessments of local transmission and
disease patterns should guide IPTi schedules.
Drug resistance
IPTi has the potential to both affect and be affected by par-
asite resistance to antimalarial drugs. The possible rela-
tionship between drug resistance and the efficacy of IPTi
has been discussed elsewhere [10]. Paradoxically, truncat-
ing an infection may interrupt the development of protec-
tive immunity leading to speculation about whether drugs
which do not completely clear an infection may be more
effective for IPTi. Data about frequencies of resistance at
or near IPTi study sites (see below) will shed light on this
relationship. The impact of IPTi on the spread of drug
resistance will be difficult to assess, particularly where the
study group is a small fraction of the community and the
drug studied is also used for treatment of malaria
episodes.
Drug pharmacokinetics
After administration of an anti-malarial drug, the concen-
tration in the bloodstream initially peaks and then gradu-
ally declines. During successful treatment, parasites are
damaged or killed by the drug and cleared by the immune
system. An infection may include a mixture of genetically
heterogeneous parasites with varying drug sensitivities.
Drug-sensitive parasites are completely cleared by drug
treatment and cannot grow in the presence of low concen-
trations of the drug. Fully resistant parasites survive "ther-
apeutic" doses of a drug, whereas partially resistant
parasites can grow in the presence of a drug, but only
when the concentration drops below a critical threshold
level (Figure 1). While the concentration remains above
the critical threshold for sensitive parasites, resistant para-
sites are selected and competition from sensitive parasites
is removed [32]. For instance, Watkins et al [33] showed
that infections detected during the clearance of SP, but
before SP concentration drops to zero (15–52 days post-
treatment), are more likely to be pyrimethamine resistant.
The spread of drug resistance is promoted by increased
transmission of resistant strains relative to sensitive strains
in the interval following drug treatment and before the
immune system succeeds in clearing parasites [34] (Figure
4a).
During chemoprophylaxis, the intention is to administer
the drug often enough to prevent plasma concentrations
from falling below the survival threshold for resistant par-
asites (Figure 1). Lack of compliance resulting in fluctua-
tions in drug concentrations increases parasite exposure to
sub-preventive/sub-curative levels and promotes the
development and spread of drug-resistant parasites. Com-
pared to chemoprophylaxis, IPTi offers the advantage of
decreased drug pressure through supervised doses that
target a specific, relatively small age group. It has the dis-
Effect of transmission intensity on outcome of IPTi Figure 2
Effect of transmission intensity on outcome of IPTi. 
Qualitative depiction of the effect of transmission intensity 
on the age-incidence pattern of malaria morbidity and mor-
tality. In areas of high transmission (solid line), malaria mor-
tality is concentrated in the first two years of life. In areas of 
low or unstable transmission (dashed line), children may be 
at risk until much later in life. The arrows represent the win-
dow of greatest risk or the age interval during which roughly 
75% of childhood malaria episodes are experienced.
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advantage of causing cyclical fluctuations of drug titres
ideal for repeated selection of resistant parasites.
IPTi studies have chosen drugs with long half-lives to
maximize the prophylactic window of each dose. How-
ever, long clearance times also lead to long periods during
which selective levels of drug are present in the blood-
stream, and, when these drugs are administered to infants,
the parasites are exposed to selective concentrations in an
immunologically naive individual. With little or no pre-
existing immunity, the host is less able to control an infec-
tion, so the potential for growth and transmission of
resistant parasites is enhanced (Figure 4b). Preliminary
results from two studies with SP in children under five
years of age show increased frequencies of infections with
SP-resistant parasites among children receiving IPT
[30,35]. It is not known how much this increase will
increase the community-wide transmission and preva-
lence of drug resistance, but several studies indicate that
infants and young children are the most important infec-
tious reservoir in a population, despite their minority [7-
9]. Prospective, community-wide, cross-sectional surveys
of molecular markers of parasite resistance before and
after implementation of IPTi could address this question.
Of course, in order to differentiate between selective pres-
sure due to conventional treatment of malaria in the com-
munity and that due to IPTi, a drug not routinely given for
febrile episodes must be chosen for IPTi in such a study.
Genetics of resistance
In infants, chemoprophylaxis decreases the multiplicity of
infections (MOI), the number of distinguishable geno-
types based on a single locus, present at any time in a sin-
gle host [36]. Assuming proportional transmission, with
fewer genotypes per host there is less potential for mating
between parasites with different alleles at resistance loci. If
resistance is conferred by alleles at two or more loci,
inbreeding reduces the opportunity for the resistance alle-
les to be separated, and thus the probability that offspring
will be susceptible. Parasite inbreeding increases the sur-
vival and prevalence of resistance genes [34].
Alternatively, IPT could increase antigenic diversification
of drug-resistant strains (Figure 5). A treatment dose will
kill all the sensitive parasites but may leave a few resistant
parasites to multiply as the drug concentration declines.
When the drug is completely cleared, the host becomes
vulnerable to infection by drug-sensitive parasites and so
may acquire multiple strains which can cross with resist-
ant parasites. The total effect is to select for resistant para-
sites, allow them to multiply without competition and
provide material for antigenic diversity in the next
Effect of transmission intensity on outcome of IPTi Figure 3
Effect of transmission intensity on outcome of IPTi. Effect of biting frequency (arrows represent infectious bites) on the 
development of malaria-specific immunity during IPTi. The frequency of infectious bites determines whether or not an infant is 
exposed to malaria parasites between doses of drug during IPTi.Malaria Journal 2005, 4:33 http://www.malariajournal.com/content/4/1/33
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generation, via cross-breeding in the mosquito, before
administering the drug again and once more selecting for
the resistant parasites.
It is not known how IPTi would affect the dynamics of
multi-strain infections, or whether IPTi would increase
parasite inbreeding, and the prevalence of resistance
genes, or increase out-crossing and the antigenic diversity
of resistant populations. Transmission intensity will
determine which, if any, of these outcomes is observed.
Because the spread of resistant parasites could be signifi-
cantly affected in either case, these potential outcomes of
IPTi should be considered in designing implementation
schemes.
Drug choice
Whether or not a particular drug is effective may be deter-
mined by the mechanism of protection of IPTi. If the pro-
phylactic period is the primary protective mechanism,
then drugs which are cleared very quickly, such as artem-
isinin, are not likely to be useful, either alone or in com-
bination with other drugs. If the primary mechanism is
clearance of existing infections, then drugs with very short
half-lives should be very effective and would decrease the
probability of accelerating the spread of resistance. Stud-
ies in mice have shown that suppression of blood-stage
infection enhances development of protective immunity
against liver-stage infection [37,38]. If the same is true in
human hosts and if infectious bites occur between doses
of drug, IPTi could protect by enhancing liver-stage
immunity. In this case, drugs active against the liver stage
of the parasite would not be effective. Several drug candi-
dates with both long and intermediate persistence times,
such as chlorproguanil/dapsone (Lapdap), SP with artesu-
nate, amodiaquine with artesunate and mefloquine, are
being tested in ongoing IPTi trials http://www.ipti-
malaria.org.
When choosing from among the effective drug candidates,
the context in which IPTi will be implemented should
also be considered, including the regional level of resist-
ance to drugs available for IPTi and the community use of
drugs for treatment of symptomatic malaria. If infants
who present with clinical malaria during IPTi are treated
with the same drug that is used for IPTi, the spread of
drug-resistant parasites may be accelerated: an infection
that appears during IPTi is more likely to be resistant to
some level of that drug, so dual usage could lead to an
increased selection and spread of highly resistant
parasites.
The studies which will be completed in the near-term are
using SP and it seems likely that SP will be the drug cho-
sen for initial implementation of IPTi. However, an anti-
folate drug closely related to SP, cotrimoxazole (trimetho-
prim-sulfamethoxazole), is currently recommended for
prophylaxis against opportunistic infections in HIV-posi-
tive individuals http://www.unaids.org/html/pub/publi
cations/irc-pub04/recommendation_en_pdf.pdf[39] and
is widely used in infants and children in malaria-endemic
areas where IPTi could be implemented. Cross-resistance
to SP and cotrimoxazole has been reported in Plasmodium
falciparum [40] and may have serious consequences for
malaria-infected patients undergoing chemoprophylaxis
with cotrimoxazole. Where there is a high prevalence of
HIV among infants at risk for malaria, the effect of cross-
resistance to cotrimoxazole on efficacy of IPTi with SP
must be evaluated and vice-versa.
Studies underway
There are several clinical trials of IPTi underway, six of
which are being conducted within the IPTi Consortium
http://www. ipti-malaria. org. The annual EIRs among
these six sites range from five to 200 infectious bites per
person, allowing comparison of efficacy data from a rela-
tively broad range of transmission conditions. However, if
Drug treatment and immune mechanisms act synergistically  to eliminate parasites Figure 4
Drug treatment and immune mechanisms act syner-
gistically to eliminate parasites. (a) A patient with some 
pre-existing immunity clears infection and reduces the 
number and transmission of the parasites that survive treat-
ment. (b) Without pre-existing immunity, the window for 
proliferation and differential transmission of resistant para-
sites is extended. White and black circles represent sensitive 
and resistant parasites, respectively.
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IPTi is uniformly administered at two, three and nine
months of age, no information about the broader applica-
bility of IPTi will be available from these studies. For
example, if IPTi delivered through EPI offers no signifi-
cant protection where the EIR is less than 50, it will be
desirable to know if different schedules might be effective.
New studies would need to be designed to answer this
question.
Since an increase in drug resistant infections [30,35] and
a rebound in malaria episodes (D. Chandramohan, per-
sonal communication) have been observed in IPTi stud-
ies, these possible adverse outcomes should be measured
in further studies. Concerns have also been raised about
the effects of IPTi on post-vaccination seroconversion
[41]. If markers of immunity, EPI seroconversion and
drug resistance data can be integrated in a meta analysis
across these diverse trials, this would provide considerable
evidence for evaluating the safety of this scheme of IPTi
implementation. This effort would require extensive
cooperation and standardized methods, but the result
would be an unprecedented ability to effectively compare
an intervention across trials in diverse malaria transmis-
sion zones. Information available online http://www.ipti-
malaria.org indicates that the IPTi Consortium is coordi-
nating its cost-effectiveness and drug safety studies in pre-
cisely this manner.
Conclusion
IPTi is a promising new intervention strategy which aims
to combine the short-term protective mechanisms of che-
moprophylaxis with the long-term protection of naturally
acquired immunity. It is certain that for some age interval,
over some time interval, IPTi would reduce the clinical
malaria case rate, whether the drug is acting as prophy-
laxis, or to clear sub-clinical infections, or both. However,
the price to be paid in the broader community, for exam-
ple in immunity and drug resistance, will be greatly
Effect of IPT on parasite diversity Figure 5
Effect of IPT on parasite diversity. Blood concentration of drug during two treatments of IPT is shown. All of the sensitive 
parasites (white circles) initially present in the host at the start of IPT are killed by the drug, leaving only resistant parasites 
(black circles). While the drug concentration is high, new infections are prevented and the resistant parasites proliferate with-
out competition. When the drug concentration falls below the threshold for sensitive parasites, an infectious bite can produce 
an infection with sensitive parasites. A subsequent bloodmeal may take up gametocytes from both sensitive (white crescents) 
and resistant strains (black crescents), thereby allowing out-crossing between them. At the next treatment, the sensitive para-
sites are killed and the resistant parasites continue to proliferate and may acquire new genetic material at the next cycle. Black 
arrows at the top represent continual biting by infectious mosquitoes.
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affected by how well IPTi deployment addresses the local
context of transmission and drug efficacy. While it is likely
that IPTi linked to EPI immunization will be salutary in
areas with intense stable transmission, much of Africa is
moving toward reduced or unstable endemicity through
urbanization and use of insecticide impregnated bednets
and other vector control strategies. If bednet use prevents
infections during the period of IPTi treatment (i.e. the first
year of life), then IPTi will not add protection. Further-
more, if, in fact, the extended protective effect of IPTi
depends on becoming infected during that period, IPTi
programmes in areas of high bednet usage may not show
the expected effects on malaria morbidity. The efficacy
and practicality of IPTi under different schedules of
administration should be explored.
To help verify that the intention of IPTi is realized, the
effects of IPTi on malaria-specific acquired immunity
should be measured and follow-up periods should
include sufficient time for rebound to be evaluated. More
thorough assessment of the potential impact of IPTi on
the spread of drug resistance is also necessary. Amplifica-
tion of drug resistance may be exacerbated by special fac-
tors connected with regimented, symptom-blind drug use
in immunologically naive infants. Site-sensitive choices of
drug and scheduling would help to minimize the amplifi-
cation and maximize the chance that it will eventually be
counter-balanced by decreased drug use later in life.
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